Product Description
Octreotide 79517-01-4
AI Product Description
*The following content is generated by AI and is for reference only.
Octreotide is a synthetic analog of natural somatostatin, widely utilized in clinical settings for the management of acromegaly and neuroendocrine tumors. Its molecular formula is C49H66N10O10S2, reflecting a complex structure comprising eight amino acids with a disulfide bridge essential for its biological stability. The substance is identified by the CAS number 8315-72-4, ensuring precise identification across pharmaceutical databases and regulatory frameworks. Unlike endogenous somatostatin, which has a very short half-life of mere minutes, Octreotide possesses an extended duration of action, allowing for less frequent dosing schedules via subcutaneous or intravenous administration.
The primary therapeutic mechanism involves binding to somatostatin receptors, particularly subtypes sst2 and sst5, thereby inhibiting the secretion of various hormones. In patients with acromegaly caused by pituitary adenomas, it effectively reduces excess growth hormone and insulin-like growth factor 1 levels, alleviating symptoms such as enlarged hands, feet, and facial features. Furthermore, Octreotide is a cornerstone treatment for carcinoid syndrome and VIPomas, conditions characterized by severe flushing, diarrhea, and electrolyte imbalances due to hormone hypersecretion. It also plays a critical role in controlling bleeding from esophageal varices associated with portal hypertension, acting by reducing splanchnic blood flow. Additionally, it is sometimes employed off-label for refractory diarrhea in AIDS patients or to manage postoperative complications like pancreatic fistulas.
Common side effects include gastrointestinal disturbances such as nausea, abdominal pain, and diarrhea, as well as gallstone formation due to reduced gallbladder motility. Long-term therapy requires monitoring of thyroid function, glucose metabolism, and cardiac rhythm. While not a cure for underlying malignancies, Octreotide significantly improves quality of life by controlling hormonal excess and tumor-related symptoms. Its versatility makes it indispensable in endocrinology and oncology, bridging the gap between symptom management and disease stabilization. As research continues, novel formulations aiming for even longer release profiles are being developed to further enhance patient compliance and therapeutic outcomes in chronic endocrine disorders.